TY - JOUR
T1 - Defining and conceptualising the commercial determinants of health
AU - Gilmore, Anna B.
AU - Fabbri, Alice
AU - Baum, Fran
AU - Bertscher, Adam
AU - Bondy, Krista
AU - Chang, Ha Joon
AU - Demaio, Sandro
AU - Erzse, Agnes
AU - Freudenberg, Nicholas
AU - Friel, Sharon
AU - Hofman, Karen J.
AU - Johns, Paula
AU - Abdool Karim, Safura
AU - Lacy-Nichols, Jennifer
AU - de Carvalho, Camila Maranha Paes
AU - Marten, Robert
AU - McKee, Martin
AU - Petticrew, Mark
AU - Robertson, Lindsay
AU - Tangcharoensathien, Viroj
AU - Thow, Anne Marie
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/4/8
Y1 - 2023/4/8
N2 - Although commercial entities can contribute positively to health and society there is growing evidence that the products and practices of some commercial actors—notably the largest transnational corporations—are responsible for escalating rates of avoidable ill health, planetary damage, and social and health inequity; these problems are increasingly referred to as the commercial determinants of health. The climate emergency, the non-communicable disease epidemic, and that just four industry sectors (ie, tobacco, ultra-processed food, fossil fuel, and alcohol) already account for at least a third of global deaths illustrate the scale and huge economic cost of the problem. This paper, the first in a Series on the commercial determinants of health, explains how the shift towards market fundamentalism and increasingly powerful transnational corporations has created a pathological system in which commercial actors are increasingly enabled to cause harm and externalise the costs of doing so. Consequently, as harms to human and planetary health increase, commercial sector wealth and power increase, whereas the countervailing forces having to meet these costs (notably individuals, governments, and civil society organisations) become correspondingly impoverished and disempowered or captured by commercial interests. This power imbalance leads to policy inertia; although many policy solutions are available, they are not being implemented. Health harms are escalating, leaving health-care systems increasingly unable to cope. Governments can and must act to improve, rather than continue to threaten, the wellbeing of future generations, development, and economic growth.
AB - Although commercial entities can contribute positively to health and society there is growing evidence that the products and practices of some commercial actors—notably the largest transnational corporations—are responsible for escalating rates of avoidable ill health, planetary damage, and social and health inequity; these problems are increasingly referred to as the commercial determinants of health. The climate emergency, the non-communicable disease epidemic, and that just four industry sectors (ie, tobacco, ultra-processed food, fossil fuel, and alcohol) already account for at least a third of global deaths illustrate the scale and huge economic cost of the problem. This paper, the first in a Series on the commercial determinants of health, explains how the shift towards market fundamentalism and increasingly powerful transnational corporations has created a pathological system in which commercial actors are increasingly enabled to cause harm and externalise the costs of doing so. Consequently, as harms to human and planetary health increase, commercial sector wealth and power increase, whereas the countervailing forces having to meet these costs (notably individuals, governments, and civil society organisations) become correspondingly impoverished and disempowered or captured by commercial interests. This power imbalance leads to policy inertia; although many policy solutions are available, they are not being implemented. Health harms are escalating, leaving health-care systems increasingly unable to cope. Governments can and must act to improve, rather than continue to threaten, the wellbeing of future generations, development, and economic growth.
UR - http://www.scopus.com/inward/record.url?scp=85151543628&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(23)00013-2
DO - 10.1016/S0140-6736(23)00013-2
M3 - Review article
SN - 0140-6736
VL - 401
SP - 1194
EP - 1213
JO - The Lancet
JF - The Lancet
IS - 10383
ER -